Press
Releases
Press Releases
AVROBIO Announces Agreement to Sell Cystinosis Gene Therapy Program for $87.5 Million
All-cash transaction, with full $87.5 million to be paid at closing Proceeds expected to extend cash runway into Q4 2024 CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 22, 2023-- AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic
May 22, 2023
AVROBIO Announces Positive Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis at the ASGCT 26th Annual Meeting
All patients remain off oral cysteamine up to 36 months post gene therapy Sustained engraftment and durable reduction in leukocyte cystine levels across all patients Received positive regulatory feedback from US and UK agencies CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 18, 2023-- AVROBIO, Inc.
May 18, 2023
AVROBIO Reports First Quarter 2023 Financial Results and Provides Business Update
On track to initiate registrational global Phase 2/3 clinical trial for Gaucher disease type 3 (GD3) in second half 2023, subject to regulatory alignment Plan to provide clinical and regulatory updates on cystinosis program in conjunction with ASGCT annual meeting in May 2023 ; plan to initiate
May 11, 2023
AVROBIO Announces Leadership Transition
Current CFO Erik Ostrowski named interim CEO, replacing Founding President and CEO Geoff MacKay CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 1, 2023-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced
May 01, 2023
AVROBIO Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update
Following positive regulatory feedback, plan to initiate registrational global Phase 2/3 clinical trial for Gaucher disease type 3 (GD3) in second half 2023, subject to regulatory alignment Patient dosing completed in collaborator-sponsored Phase 1/2 clinical trial for cystinosis; plan to initiate
Mar 23, 2023
AVROBIO to Participate in Cowen’s 43rd Annual Health Care Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 3, 2023-- AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in a panel titled
Mar 03, 2023
AVROBIO to Present Clinical and Preclinical Data from Lysosomal Disorder Gene Therapy Pipeline at WORLDSymposium™ 2023
Four platform presentations and two posters with data on AVROBIO’s lysosomal disorder programs to be presented CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 9, 2023-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease,
Feb 09, 2023
AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 5, 2023-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that the company has granted an aggregate of 7,500 restricted stock units (RSUs) to one new